The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bulimia


Psychiatry related information on Bulimia


High impact information on Bulimia

  • Impaired cholecystokinin secretion in bulimia nervosa [11].
  • Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial [12].
  • Since meal termination and satiety are mainly vagally mediated functions, since binge-eating and vomiting produce intense stimulation of vagal afferent fibres, and since ondansetron and other 5-HT3 antagonists decrease afferent vagal activity, the symptom improvement may result from a pharmacological correction of abnormal vagal neurotransmission [12].
  • L-tryptophan as an adjunct to treatment of bulimia nervosa [13].
  • A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder [14].

Chemical compound and disease context of Bulimia


Biological context of Bulimia


Anatomical context of Bulimia


Gene context of Bulimia

  • In particular, we found no evidence for an increased rate of binge-eating behavior in obese carriers of MC4R variants [29].
  • RESULTS: A highly significant association was observed between the IGF2 ApaI G allele and scores on the Eating Attitudes Test overall and each of its subscales (bulimia, dieting, and oral control) [30].
  • METHODS: Plasma leptin and cerebrospinal fluid leptin, NPY, and PYY concentrations were measured in women who were recovered from anorexia or bulimia nervosa to determine whether alterations persisted after recovery [31].
  • We compared rates of binge eating behavior in the two genotypic groups defined by the presence or absence of the seven-repeat allele of DRD4 [32].
  • Alterations in neuropeptide Y and/or peptide YY are suggested to play a role in the pathophysiology of bulimia [33].

Analytical, diagnostic and therapeutic context of Bulimia


  1. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. Lubrano-Berthelier, C., Dubern, B., Lacorte, J.M., Picard, F., Shapiro, A., Zhang, S., Bertrais, S., Hercberg, S., Basdevant, A., Clement, K., Vaisse, C. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  2. Prefrontal and striatal dopamine metabolism during enhanced rebound hyperphagia induced by space restriction--a rat model of binge eating. Inoue, K., Kiriike, N., Okuno, M., Fujisaki, Y., Kurioka, M., Iwasaki, S., Yamagami, S. Biol. Psychiatry (1998) [Pubmed]
  3. Opposite changes in circulating adiponectin in women with bulimia nervosa or binge eating disorder. Monteleone, P., Fabrazzo, M., Martiadis, V., Fuschino, A., Serritella, C., Milici, N., Maj, M. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  4. Platelet alpha 2-adrenoceptor and adenylate cyclase in patients with anorexia nervosa and bulimia. Heufelder, A., Warnhoff, M., Pirke, K.M. J. Clin. Endocrinol. Metab. (1985) [Pubmed]
  5. Polycystic ovary syndrome, gestational diabetes, and bulimia nervosa. Morgan, J.F. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  6. Changes in melatonin levels but not cortisol levels are associated with depression in patients with eating disorders. Kennedy, S.H., Garfinkel, P.E., Parienti, V., Costa, D., Brown, G.M. Arch. Gen. Psychiatry (1989) [Pubmed]
  7. Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia. Brewerton, T.D., Mueller, E.A., Lesem, M.D., Brandt, H.A., Quearry, B., George, D.T., Murphy, D.L., Jimerson, D.C. Arch. Gen. Psychiatry (1992) [Pubmed]
  8. Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Fava, M., Copeland, P.M., Schweiger, U., Herzog, D.B. The American journal of psychiatry. (1989) [Pubmed]
  9. Dimensions of religiosity and their relationship to lifetime psychiatric and substance use disorders. Kendler, K.S., Liu, X.Q., Gardner, C.O., McCullough, M.E., Larson, D., Prescott, C.A. The American journal of psychiatry. (2003) [Pubmed]
  10. Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Nakazato, M., Hashimoto, K., Shimizu, E., Kumakiri, C., Koizumi, H., Okamura, N., Mitsumori, M., Komatsu, N., Iyo, M. Biol. Psychiatry (2003) [Pubmed]
  11. Impaired cholecystokinin secretion in bulimia nervosa. Geracioti, T.D., Liddle, R.A. N. Engl. J. Med. (1988) [Pubmed]
  12. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Faris, P.L., Kim, S.W., Meller, W.H., Goodale, R.L., Oakman, S.A., Hofbauer, R.D., Marshall, A.M., Daughters, R.S., Banerjee-Stevens, D., Eckert, E.D., Hartman, B.K. Lancet (2000) [Pubmed]
  13. L-tryptophan as an adjunct to treatment of bulimia nervosa. Mira, M., Abraham, S. Lancet (1989) [Pubmed]
  14. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Appolinario, J.C., Bacaltchuk, J., Sichieri, R., Claudino, A.M., Godoy-Matos, A., Morgan, C., Zanella, M.T., Coutinho, W. Arch. Gen. Psychiatry (2003) [Pubmed]
  15. Decreased serotonin function in bulimia nervosa. Jimerson, D.C., Wolfe, B.E., Metzger, E.D., Finkelstein, D.M., Cooper, T.B., Levine, J.M. Arch. Gen. Psychiatry (1997) [Pubmed]
  16. Association of serotonin and cortisol indices with childhood abuse in bulimia nervosa. Steiger, H., Gauvin, L., Israël, M., Koerner, N., Ng Ying Kin, N.M., Paris, J., Young, S.N. Arch. Gen. Psychiatry (2001) [Pubmed]
  17. Dexamethasone suppression test and plasma dexamethasone levels in bulimia. Walsh, B.T., Lo, E.S., Cooper, T., Lindy, D.C., Roose, S.P., Gladis, M., Glassman, A.H. Arch. Gen. Psychiatry (1987) [Pubmed]
  18. Treatment of bulimia with phenelzine. A double-blind, placebo-controlled study. Walsh, B.T., Stewart, J.W., Roose, S.P., Gladis, M., Glassman, A.H. Arch. Gen. Psychiatry (1984) [Pubmed]
  19. Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa. Weltzin, T.E., Fernstrom, M.H., Fernstrom, J.D., Neuberger, S.K., Kaye, W.H. The American journal of psychiatry. (1995) [Pubmed]
  20. Eating disorders in males: a report on 135 patients. Carlat, D.J., Camargo, C.A., Herzog, D.B. The American journal of psychiatry. (1997) [Pubmed]
  21. Disturbances in the hypothalamo-pituitary-adrenal and other neuroendocrine axes in bulimia. Fichter, M.M., Pirke, K.M., Pöllinger, J., Wolfram, G., Brunner, E. Biol. Psychiatry (1990) [Pubmed]
  22. Postprandial cholecystokinin release and gastric emptying in patients with bulimia nervosa. Devlin, M.J., Walsh, B.T., Guss, J.L., Kissileff, H.R., Liddle, R.A., Petkova, E. Am. J. Clin. Nutr. (1997) [Pubmed]
  23. Symptom fluctuation in bulimia nervosa: relation to menstrual-cycle phase and cortisol levels. Lester, N.A., Keel, P.K., Lipson, S.F. Psychological medicine. (2003) [Pubmed]
  24. Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Jimerson, D.C., Lesem, M.D., Kaye, W.H., Brewerton, T.D. Arch. Gen. Psychiatry (1992) [Pubmed]
  25. [123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Tauscher, J., Pirker, W., Willeit, M., de Zwaan, M., Bailer, U., Neumeister, A., Asenbaum, S., Lennkh, C., Praschak-Rieder, N., Brücke, T., Kasper, S. Biol. Psychiatry (2001) [Pubmed]
  26. Plasma ghrelin in anorexia, bulimia, and binge-eating disorder: relations with eating patterns and circulating concentrations of cortisol and thyroid hormones. Troisi, A., Di Lorenzo, G., Lega, I., Tesauro, M., Bertoli, A., Leo, R., Iantorno, M., Pecchioli, C., Rizza, S., Turriziani, M., Lauro, R., Siracusano, A. Neuroendocrinology (2005) [Pubmed]
  27. Blood platelet monoamine oxidase activity, serotonin uptake and release rates in anorexia and bulimia patients and in healthy controls. Hallman, J., Sakurai, E., Oreland, L. Acta psychiatrica Scandinavica. (1990) [Pubmed]
  28. Beta 2-adrenergic receptor regulation in circulating mononuclear leukocytes in anorexia nervosa and bulimia. Lonati-Galligani, M., Pirke, K.M. Psychiatry research. (1986) [Pubmed]
  29. Binge-eating episodes are not characteristic of carriers of melanocortin-4 receptor gene mutations. Hebebrand, J., Geller, F., Dempfle, A., Heinzel-Gutenbrunner, M., Raab, M., Gerber, G., Wermter, A.K., Horro, F.F., Blundell, J., Schäfer, H., Remschmidt, H., Herpertz, S., Hinney, A. Mol. Psychiatry (2004) [Pubmed]
  30. Association between the insulin-like growth factor 2 gene (IGF2) and scores on the Eating Attitudes Test in nonclinical subjects: a family-based study. Bachner-Melman, R., Zohar, A.H., Nemanov, L., Heresco-Levy, U., Gritsenko, I., Ebstein, R.P. The American journal of psychiatry. (2005) [Pubmed]
  31. Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Gendall, K.A., Kaye, W.H., Altemus, M., McConaha, C.W., La Via, M.C. Biol. Psychiatry (1999) [Pubmed]
  32. The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Levitan, R.D., Masellis, M., Basile, V.S., Lam, R.W., Kaplan, A.S., Davis, C., Muglia, P., Mackenzie, B., Tharmalingam, S., Kennedy, S.H., Macciardi, F., Kennedy, J.L. Biol. Psychiatry (2004) [Pubmed]
  33. An approach to the development of drugs for appetite disorders. Morley, J.E. Neuropsychobiology (1989) [Pubmed]
  34. Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Goldbloom, D.S., Olmsted, M.P. The American journal of psychiatry. (1993) [Pubmed]
  35. CSF beta-endorphin and dynorphin in bulimia nervosa. Brewerton, T.D., Lydiard, R.B., Laraia, M.T., Shook, J.E., Ballenger, J.C. The American journal of psychiatry. (1992) [Pubmed]
  36. Greater left cerebral hemispheric metabolism in bulimia assessed by positron emission tomography. Wu, J.C., Hagman, J., Buchsbaum, M.S., Blinder, B., Derrfler, M., Tai, W.Y., Hazlett, E., Sicotte, N. The American journal of psychiatry. (1990) [Pubmed]
  37. Polymorphism of the serotonin 5-HT1B receptor gene (HTR1B) associated with minimum lifetime body mass index in women with bulimia nervosa. Levitan, R.D., Kaplan, A.S., Masellis, M., Basile, V.S., Walker, M.L., Lipson, N., Siegel, G.I., Woodside, D.B., Macciardi, F.M., Kennedy, S.H., Kennedy, J.L. Biol. Psychiatry (2001) [Pubmed]
WikiGenes - Universities